期刊文献+

多发性骨髓瘤肾损害早期评估的探讨 被引量:7

Exploration of early assessment of renal impairment in multiple myeloma
原文传递
导出
摘要 目的探讨血半胱氨酸蛋白酶抑制剂C(血Cys—C)、尿半胱氨酸蛋白酶抑制剂C(尿Cys-C)、尿视黄醇结合蛋白(RBP)、尿中性粒细胞明胶酶相关载脂蛋白(NGAL)在早期评估多发性骨髓瘤(MM)肾损害中的作用及在MM不同病理类型肾损害中的变化特点。方法根据肾少球滤过率估计值将MM患者分成两组,A组为肾功能正常组,B组为。肾功能损害组。以同期性别和年龄相匹配的健康志愿者为对照。检测患者血Cys-C、尿Cys-C、尿RBP、尿NGAL及血清肌酐(Scr)、尿微量蛋白(MAU)、尿d1一微球蛋白(α1—MG),同时对血Cys-C、尿Cys-C、尿RBP、尿NGAL异常且有意愿的患者行肾穿刺活检。结果①A组MM患者与健康对照组相比,血Cys—C、尿RBP、尿Cys—C、尿NGAL均高于健康对照组(P值均〈0.05)。6例实验指标异常的A组患者行。肾穿刺活检术,活检结果提示均有不同程度的肾损害,且血Cys—C、尿Cys—C、尿RBP、尿NGAL异常率分别为66.7%、66.7%、66.7%、83.3%。@24例实验指标异常的MM患者行肾穿刺活检术,其中淀粉样变性组6例,管型肾病(CN)组12例,免疫球蛋白沉积病(MIDD)组6例。CN组与MIDD组、淀粉样变性组相比,尿Cys—C、尿NGAL明显升高(P〈0.05)。MIDD组与CN组、淀粉样变性组相比,尿RBP明显升高(P=0.043)。淀粉样变性组与CN组、MIDD组相比,MAU明显升高(P=0.006)。结论与传统指标相比,血Cys—C、尿Cys.C、尿RBP、尿NGAL能更有效地早期评估MM患者肾损害。淀粉样变性组患者MAU明显升高,CN组患者尿Cys—C、尿NGAL明显升高,MIDD组患者尿RBP明显升高。 Objective To investigate the value of serum cystatin C (Cys-C), urinary Cys-C, urinary retinol binding protein (RBP) and urinary neutrophil gelatinase-associated lipocalin (NGAL) in the early assessment of multiple myeloma ( MM ) and their characteristic changes in different pathological types of renal impaitment. Methods According to glomerular filtration rate ( eGFR), the patients were divided into two groups, of which marked group A with normal renal function, the other marked group B with abnormal renal function. Sixty healthy subjects were chosen as control. Detection of the serum Cys-C, urinary RBP, urinary Cys-C, urinary NGAL, serum creatinine (Scr) , urinary microalbumin (MAU) and urinary ctl-microglobulin (or1-MG) were performed. Renal biopsy was carried out for patients who had abnormal serum Cys-C, urinary Cys-C, urinary RBP, urinary NGAL and were willing to accept further test. Results Compared with healthy controls, the serum Cys-C, urinary RBP, urinary Cys-C, urinary NGAL of group A were significantly higher than that of healthy controls. Six group A patients received renal biopsy, and varying degrees of renal damage were discovered. The serum Cys-C, urinary RBP, urinary Cys-C and urinary NGAL positive rate were 66.7% , 66.7% , 66.7% and 83.3%, respectively. Of twenty-four cases received biopsy after abnormal examination results were shown, six turned out to be amyloidosis, twelve cast nephropathy (CN) and 6 monoclonal immunoglobulin deposition disease (MIDD). Compared with MIDD and amyloidosis, the urinary Cys-C and NGAL of the CN group are significantly higher (P 〈 0.05 ). Compared with CN and amyloidosis, urinary RBP of MIDD is significantly higher (P = 0.043). Compared with MIDD and CN, the MAU of amyloidosis is significantly higher (P = O. 006). Conclusion Compared with the conventional indicators, serum Cys-C, urinary Cys-C, RBP and NGAL are more sensitive in early assessment of MM patients with renal damage. The MAU is higher in amyloid, the urinary Cys-C and urinary NGAL are significantly elevated in CN, the urinary RBP is significantly elevated in MIDD.
出处 《中华血液学杂志》 CAS CSCD 北大核心 2012年第10期819-822,共4页 Chinese Journal of Hematology
关键词 多发性骨髓瘤 肾损害 病理学 临床 Multiple myeloma Renal impairment Pathology, clinical
  • 相关文献

参考文献1

二级参考文献6

  • 1李惊子 谌贻璞 等.应用相差显微镜鉴别血尿的来源[J].中华内科杂志,1984,23(11):688-691.
  • 2Jung K,Pergande M,Schimke E,et al . Urinary enzymes and low- molecular-mass proteins as indicators of diabetic nephropathy [J] . Clin Chem, 1988,34,544.
  • 3Marcussen N, Schumann J, Campbell P, Kjellstrand C. Cytodiagnostic urinalysis is very useful in the differential diagnosis of acute renal failure and can predict the severity [J] . Ren Fail, 1995 Nov, 17(6): 721-729.
  • 4Fogazzi GB,Saglimbeni L,Banfi G,et al . Urinary sediment features in proliferative and non-proliferative glomerular diseases [J] . J Nephrol,2005 Nov-Dec, 18(6):703-710.
  • 5金顺英,王磊.应进一步认识尿沉渣镜检分析的重要意义[J].中国实验诊断学,2000,4(3):149-150. 被引量:7
  • 6刘彩艳,魏健,刘彩艳,魏健.尿RBP和NAG与糖尿病肾病早期病变的关系[J].辽宁实用糖尿病杂志,2004,12(2):28-29. 被引量:9

共引文献3

同被引文献66

  • 1李娟,熊文杰,罗绍凯,邹外一,张国材.多发性骨髓瘤骨髓单个核细胞PTEN mRNA的表达[J].中国肿瘤临床与康复,2004,11(5):398-400. 被引量:3
  • 2叶海格,沈志坚,俞康,梁彬.DTPACE化疗方案治疗难治性多发性骨髓瘤六例临床疗效观察[J].中国肿瘤临床与康复,2007,14(1):70-71. 被引量:1
  • 3侯建,傅卫军.多发性骨髓瘤及其相关疾病[M].上海:上海科学技术出版社,2002:10.
  • 4叶任高,陆再英.内科学[M].第6版.北京:人民卫生出版社,2006:787-788.
  • 5张之南,沈悌.血液病诊断及疗效标准[M].第3版.北京:科学出版社,2008.232-235.
  • 6田超,张示渊,蒲瑞.血细胞形态学复检及对血液系统疾病的临床应用[J].农垦医学,2007,29(4):277-278. 被引量:2
  • 7许文英,王建中.临床血液学与检验[M].第4版.北京:人民卫生出版社.2007:300.
  • 8Dimopoulos MA,Delimpasi S,Katodritou E,et al.Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents[J].Ann Oncol,2014,25:195-200.
  • 9Dimopoulos MA,Roussou M,Gkotzamanidou M,et al.The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma[J].Leukemia,2013,27:423-429.
  • 10Stratta P,Airoldi A,Battista M,et al.Comment on:Think to prevent before than to treat renal impairment in multiple myeloma:do not forget tubular damage mimicking fanconi syndrome[J].Expert Opin Pharmacother,2014,15:299-300.

引证文献7

二级引证文献36

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部